Company / Working Capital
Arcadia Biosciences, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$4.3M
FY2025
5-year range
$4.3M / $30.3M
FY2021-FY2025
Trend
-35.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $30M in FY2021 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -29.9%.
Declined from $11M to $4M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -41.2%
- 5-Year CAGR
- -29.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Arcadia Biosciences, Inc.'s working capital has declined for 4 consecutive years.
- 5-year CAGR of -29.9%, indicating a declining trend.
- In FY2025, working capital decreased 35.7% year-over-year.
- Peak working capital was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3M | -35.7% |
| FY2024 | $6.7M | -41.3% |
| FY2023 | $11.4M | -46.3% |
| FY2022 | $21.2M | -30.2% |
| FY2021 | $30.3M | +19.6% |
| FY2020 | $25.4M | +11.7% |
| FY2019 | $22.7M | +14.7% |
| FY2018 | $19.8M | +72.0% |
| FY2017 | $11.5M | -76.5% |
| FY2016 | $49.1M | +1.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026